Matches in Wikidata for { <http://www.wikidata.org/entity/Q63587771> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q63587771 description "clinical trial" @default.
- Q63587771 description "ensayu clínicu" @default.
- Q63587771 description "klinisch onderzoek" @default.
- Q63587771 description "клінічне випробування" @default.
- Q63587771 description "կլինիկական փորձարկում" @default.
- Q63587771 name "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis" @default.
- Q63587771 type Item @default.
- Q63587771 label "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis" @default.
- Q63587771 prefLabel "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis" @default.
- Q63587771 P1050 Q63587771-EF33CB1F-3544-4422-9C2E-DE1B941CDFE4 @default.
- Q63587771 P1132 Q63587771-39D0F9A6-3306-4614-8C2C-ACE9C56D55D6 @default.
- Q63587771 P1476 Q63587771-ABE1571E-108B-4E92-80B3-F1BE16308E44 @default.
- Q63587771 P17 Q63587771-07FA3D09-AC28-4D03-8AB9-6DD3EF0F5A15 @default.
- Q63587771 P17 Q63587771-989AAFD4-F5D4-4ED1-AC8E-0050921DC921 @default.
- Q63587771 P2899 Q63587771-3E1353ED-D98A-4ECB-8D1E-094AB2267E33 @default.
- Q63587771 P3098 Q63587771-DF238430-D88D-4EA2-81AA-1ED5817FE9BA @default.
- Q63587771 P31 Q63587771-E2114F18-87BF-45C3-9883-084C3BADA8A0 @default.
- Q63587771 P580 Q63587771-25CDEB23-226E-4C31-9C2B-ABD997462C09 @default.
- Q63587771 P582 Q63587771-406A9320-1728-4C86-9A4B-3932A9D105F0 @default.
- Q63587771 P6099 Q63587771-EF5769E7-D6C8-4DE6-8D3B-695B42E260F6 @default.
- Q63587771 P6153 Q63587771-170E9BE9-C1C0-4FF0-B537-9BBA85B95605 @default.
- Q63587771 P6153 Q63587771-3870DED1-4E31-44D8-BD01-148AD0D7E145 @default.
- Q63587771 P6153 Q63587771-471C2636-451F-47BF-ACB8-0EE619E1BB70 @default.
- Q63587771 P6153 Q63587771-57F5C8BD-A7CF-431A-B09D-161DFA72002E @default.
- Q63587771 P6153 Q63587771-5D1C369D-0533-4ADC-8F61-FCBB3748A8B7 @default.
- Q63587771 P6153 Q63587771-71252A67-A43A-4F0A-B344-8EF96F00D057 @default.
- Q63587771 P6153 Q63587771-FBBBEAFF-A5A2-455F-B969-511CCDC30436 @default.
- Q63587771 P8363 Q63587771-2BBF31F6-7118-4C07-949C-D721D1D77550 @default.
- Q63587771 P1050 Q112670 @default.
- Q63587771 P1132 "+112" @default.
- Q63587771 P1476 "A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy" @default.
- Q63587771 P17 Q30 @default.
- Q63587771 P17 Q31 @default.
- Q63587771 P2899 "+18" @default.
- Q63587771 P3098 "NCT03731260" @default.
- Q63587771 P31 Q30612 @default.
- Q63587771 P580 "2019-04-16T00:00:00Z" @default.
- Q63587771 P582 "2020-12-01T00:00:00Z" @default.
- Q63587771 P6099 Q42824440 @default.
- Q63587771 P6153 Q1159198 @default.
- Q63587771 P6153 Q28207111 @default.
- Q63587771 P6153 Q30253941 @default.
- Q63587771 P6153 Q3145237 @default.
- Q63587771 P6153 Q41506 @default.
- Q63587771 P6153 Q56582915 @default.
- Q63587771 P6153 Q850730 @default.
- Q63587771 P8363 Q78089383 @default.